scholarly journals PD59-06 TWO-YR ONCOLOGIC OUTCOMES OF OPEN VS ROBOTIC RADICAL CYSTECTOMY: FOCUS ON RECURRENCE SITES FROM A PROSPECTIVE-RANDOMIZED STUDY

2021 ◽  
Vol 206 (Supplement 3) ◽  
Author(s):  
Mariaconsiglia Ferriero ◽  
Riccardo Mastroianni ◽  
Gabriele Tuderti ◽  
Umberto Anceschi ◽  
Leonardo Misuraca ◽  
...  
Keyword(s):  
Radical Cystectomy ◽  
Randomized Study ◽  
Oncologic Outcomes ◽  
Prospective Randomized Study ◽  
Robotic Radical Cystectomy ◽  
Recurrence Sites

Two-yr oncologic outcomes of ORC vs. RARC: Focus on recurrence sites from a prospective-randomized study

2021 ◽  
Vol 79 ◽  
pp. S1133-S1134
Author(s):  
M.C. Ferriero ◽  
R. Mastroianni ◽  
G. Tuderti ◽  
U. Anceschi ◽  
A. Brassetti ◽  
...  
Keyword(s):  
Randomized Study ◽  
Oncologic Outcomes ◽  
Prospective Randomized Study ◽  
Recurrence Sites

scholarly journals Blood loss associated with radical cystectomy: A prospective, randomized study comparing Impact LigaSure vs. stapling device

2014 ◽  
Vol 32 (1) ◽  
pp. 45.e11-45.e15 ◽  
Author(s):  
Ian M. Thompson ◽  
Stephen F. Kappa ◽  
Todd M. Morgan ◽  
Daniel A. Barocas ◽  
Carl J. Bischoff ◽  
...  
Keyword(s):  
Blood Loss ◽  
Radical Cystectomy ◽  
Randomized Study ◽  
Prospective Randomized Study ◽  
Stapling Device

Robotic radical cystectomy: Medium-term oncologic follow-up.

2011 ◽  
Vol 29 (7_suppl) ◽  
pp. 288-288 ◽  
Author(s):  
C. Mmeje ◽  
R. Nunez-Nateras ◽  
R. Pruthi ◽  
M. E. Nielsen ◽  
E. Wallen ◽  
...  
Keyword(s):  
Radical Cystectomy ◽  
Case Series ◽  
Oncologic Outcomes ◽  
Medium Term ◽  
Recurrence Rates ◽  
Time To Recurrence ◽  
Robotic Radical Cystectomy ◽  
The Mean ◽  
Open Radical Cystectomy

288 Background: We report our experience with robot assisted radical cystectomy (RARC) with regard to medium-term (at least 2 year) oncologic outcomes. Methods: A total of 275 patients have undergone RARC and urinary diversion at two institutions for invasive bladder cancer between 2005-present. We performed a retrospective analysis of the 139 patients who underwent RARC with a minimum of 2 years follow-up. Medium term oncologic outcomes including recurrence rates, time to recurrence, recurrence free survival (RFS), disease specific survival (DSS) were analyzed. Follow-up was measured from time of surgery to time of most recent clinical follow-up. Results: This cohort of patients consisted of 108 men (78%) and 31 women (22%) at a mean age of 67.3 years (range 45-86 years). Sixty-one (44%) patients had ≤ pT2 disease, 38 (27%) pT3/T4 disease, and 40 (29%) N+ disease. The mean number of lymph nodes removed was 18 (range 3-41). The average clinical follow up in this case series was nearly 3 years with a mean of 35.9 months (range 24-64 months). At this follow-up, 39 patients have recurred, 27 patients died of disease, and 5 patients died of other causes giving an overall RFS, DSS, and OS rates of 80%, 71%, and 68%, respectively. The mean (median) time to recurrence was 12.3 months (10 months). These findings are consistent with prior reports of the oncologic outcomes for open radical cystectomy. Conclusions: The oncologic follow-up of patients undergoing RARC appears to be favorable with acceptable outcomes in the medium-term (mean – 3 years). As our follow-up increases, we should expect to truly define the long-term clinical appropriateness and oncologic success of this procedure. No significant financial relationships to disclose.

1600 ONCOLOGIC OUTCOMES FOR NODE-POSITIVE PATIENTS UNDERGOING ROBOTIC RADICAL CYSTECTOMY

2011 ◽  
Vol 185 (4S) ◽  
Author(s):  
Chinedu Mmeje ◽  
Rafael Nunez ◽  
Raj Pruthi ◽  
Matthew Nielsen ◽  
Eric Wallen ◽  
...  
Keyword(s):  
Radical Cystectomy ◽  
Oncologic Outcomes ◽  
Node Positive ◽  
Robotic Radical Cystectomy
Sign in / Sign up

Export Citation Format

Share Document